Invitation to a Presentation of the 1st Quarter 2022 Results

Oncoinvent would like to extend an invitation to a presentation of the Q1 2022 results. The presentation will be held on Wednesday 1. June 2022 at 08:30 AM in the offices of the company at Gullhaugsveien 7, Oslo, 3rd Floor.

To attend, please register with kvam@oncoinvent.com.

Oncoinvent ønsker med dette å invitere til presentasjon av resultater for 1. kvartal 2022. Presentasjonen vil holdes onsdag 1. juni 2022, kl. 08:30 i selskapets lokaler i Gullhaugsveien 7, Oslo, 3. etasje.

Vi ber om at deltakere registrerer seg ved å sende en e-post til kvam@oncoinvent.com.

Organiser: Oncoinvent
Venue:

Gullhaugsveien 7, Oslo, 3rd Floor.


Date: 1 June 2022
Program:

About

Management

Board of Directors

Radspherin®

Pipeline

Publications

News

Events

Newsletter subscription

Reports and presentations

Largest shareholders

IR Contact

+47 22 18 33 05

Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway

© Oncoinvent. All rights reserved. Design by Anagram Design AS

Jan Alan Alfheim

Chief Executive Officer

alfheim@oncoinvent.com

+47 464 40 045

Jan A. Alfheim is a business executive with over thirty years’ experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch.

With experience in research, project management, business development & partnering, company start-ups, and product launches, Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held various senior roles including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Mr. Alfheim holds a MSc from Concordia University and a MBA from McGill University.

close